GlassScriptPhysician profile
Rebecca Iroha
NPI 1437506185
$1,782.38
in general payments reported to CMS, 2019-2025
23 companies · $890 in 2025
The $890 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $403 · 2024: $490 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760 · Education: $22.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,759.51 |
| Education | $22.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $213.59 | 2023 | Remicade, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $195.82 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $194.12 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.10 | 2023-2025 | Trulance, Xifaxan |
| Ardelyx, INC. | $184.58 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $116.72 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $98.19 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $75.93 | 2025 | Tremfya |
| Vivus LLC | $68.67 | 2024-2025 | Pancreaze, Qsymia |
| Lilly USA, LLC | $60.99 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $60.27 | 2023-2024 | Dificid |
| Madrigal Pharmaceuticals | $48.28 | 2025 | Rezdiffra |
| Celltrion USA INC. | $39.23 | 2023-2025 | Yuflyma, Vegzelma |
| Intercept Pharmaceuticals, INC. | $33.24 | 2024-2025 | |
| Pfizer INC. | $31.08 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle Biologics, INC | $27.98 | 2025 | Photofrin |
| Fresenius Kabi USA, LLC | $26.75 | 2024 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $24.56 | 2024 | Zeposia |
| Novo Nordisk INC | $20.48 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $19.99 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.38 | 2023 | Cyltezo |
| Celgene Corporation | $18.91 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $14.52 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Iroha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.